Supplementary Table S3 showed the genotype frequency of CYP3A5*3. Pharmacokinetics of MDZ in wild-type CYP3A5 showed an increase in AUC0-last (2.53 fold), AUC0-inf (2.57 fold), and Cmax (1.83 fold) in elderly patients with CKD as compared to healthy young participants (Supplementary Table S6). Pharmacokinetics profiles of MDZ between CPY3A5 genetic variants (6968AG and 6986GG) and wild type (6986AA) were also compared in healthy young participants. There were no differences observed between them (Supplementary Table S7). The gene discussed is CYP3A5; the disease is chronic kidney disease.